Role of fluticasone propionate in the treatment of children's snoring effected by adenoidal hypertrophy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17013596

Enrollment

Unknown

Registered

2017-11-29

Start date

2013-01-01

Completion date

Unknown

Last updated

2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenoidal hypertrophy

Interventions

moderate adenoidal hypertrophy:Medicine therapy

severe adenoidal hypertrophy:Medicine therapy

Eligibility

Sex/Gender

All

Age

3 Years to 12 Years

Inclusion criteria

Inclusion criteria: children with snoring from January 2013 to December 2016, who were diagnosed of adenoidal hypertrophy by nasopharyngeal radiographs

Exclusion criteria

Exclusion criteria: Children with concomitant tonsillar hypertrophy, positive history of allergy or atopy, upper respiratory infection within the past 2 weeks, nasal anatomic anomalies (eg, nasal septum deviation) or sinonasal diseases such as hypertrophy of inferior turbinates and/or nasal polyposis, craniofacial malformations including labiopalatal clefts, genetic diseases (eg, Down syndrome),neurologic disorders, cardiovascular diseases, immunodeficiency, history of epistaxis, hypersensitivity to steroids, or intranasal, topical, or systemic steroid or antibiotic treatment within the past 4 weeks were excluded.

Design outcomes

Primary

Measure	Time frame
AN ratio;symptom score;	—

Countries

China

Contacts

Public ContactHanzhong Duan

Zhejiang Xiaoshan Hospital

duanent@sina.com+86 18969979606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026